Roivant reports positive Phase 2 brepocitinib data in CS; Q3 loss $313.7M vs $208.9M

Roivant Sciences Ltd.

2025-Q3 EPS reported -$0.88 revenue$5,740,000

Phase 2 BEACON study: brepocitinib 45mg achieved 22.3-point CSAMI-A improvement vs 0.7 placebo (Δ21.6, p<0.0001).
NDA submitted to FDA for brepocitinib in dermatomyositis; Phase 3 CS study planned for 2026.
Q3 loss from continuing ops $313.7M ($0.38/share) vs $208.9M ($0.22); revenue fell to $2M from $9M.
Cash and marketable securities of $4.5B as of Dec 31, 2025; R&D expenses rose to $165.4M.
Immunovant's IMVT-1402 D2T RA trial fully enrolled; Genevant jury trial set for Mar 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.